Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prescription savings may look simple on the GoodRx app, but the company’s disclosures tell a deeper story of PBM economics, subscription growth, and regulatory scrutiny. If you came searching for “GoodRx SEC filings explained simply” or wondered, “Where can I find the GoodRx annual report 10-K simplified?”, you’re in the right place. Stock Titan’s AI reads each page—whether a 300-page 10-K or a same-day 8-K—and surfaces what matters: PBM concentration risk, monthly active consumer trends, and the real cost of prescription transactions.
Use our dashboard to jump straight into GoodRx quarterly earnings report 10-Q filing summaries, monitor GoodRx insider trading Form 4 transactions, and receive GoodRx Form 4 insider transactions real-time alerts. Our technology converts dense footnotes into plain language, so understanding GoodRx SEC documents with AI feels intuitive, not intimidating. Curious about executive pay? The GoodRx proxy statement executive compensation section is distilled into key figures and policy changes. Need context on sudden announcements? Check the GoodRx 8-K material events explained card for instant clarity.
Every filing type is covered and updated the moment EDGAR posts it—10-Ks, 10-Qs, 8-Ks, DEF 14As, S-8s, even Section 16 reports. Investors rely on our AI-powered summaries to perform GoodRx earnings report filing analysis, trace GoodRx executive stock transactions Form 4, and benchmark telehealth revenue streams without wading through legalese. Whether you’re tracking margin trends or validating insider purchase signals, Stock Titan equips you with concise insights, real-time data, and direct links to the source documents so you can act decisively.
Agnes Rey-Giraud transferred 75,219 shares of GoodRx Holdings, Inc. (GDRX) Class A common stock to the ARG Family Legacy Trust #1 on 08/18/2025. The Form 4 shows the Reporting Person serves as sole trustee of the Trust and that members of her family are beneficiaries. After the transaction the filings indicate beneficial ownership entries reflecting the transfer; the Form 4 was signed by an attorney-in-fact on 08/19/2025. The document contains no information about sales, option exercises, or cash consideration beyond the transfer into the Trust.
GoodRx Holdings insider Nabiey Romin reported transactions on 08/15/2025. 4,804 restricted stock units were converted into 4,804 shares of Class A common stock (transaction code M), increasing reported beneficial ownership to 139,011 shares. On the same day a separate sale (transaction code F) disposed of 1,719 shares at $3.54 per share, reducing beneficial ownership to 137,292. The filing shows 67,258 underlying shares remain from outstanding restricted stock units. The RSU vesting schedule is explicit: 6.25% vested May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters. The form is signed by an attorney-in-fact on behalf of the reporting person.
On 08/08/2025 Nabiey Romin, Chief Accounting Officer of GoodRx Holdings, Inc. (GDRX), reported the vesting of 12,663 restricted stock units (RSUs) and a disposition of 4,531 Class A common shares at a price of $3.47 per share. The Form 4 is signed by Gracye Cheng, Attorney-in-Fact, dated 08/08/2025.
The filing shows beneficial ownership following these transactions of 134,207 Class A shares (direct) and 88,639 derivative securities reported as direct holdings. The RSU disclosure states each unit equals one share, with 6.25% vested on August 8, 2023 and the remaining 93.75% vesting in equal quarterly installments over 15 quarters.
Spectrum Equity reduces, but still retains a significant position in GoodRx Holdings, Inc. (NASDAQ: GDRX) according to Amendment No. 6 to its Schedule 13D. The filing reflects events through 2 July 2025 and amends the original Schedule 13D first filed in June 2021 and most recently updated in June 2025.
Key ownership data: the five affiliated reporting entities — Spectrum Equity VII, L.P.; Spectrum Equity Associates VII, L.P.; Spectrum VII Investment Managers’ Fund, L.P.; Spectrum VII Co-Investment Fund, L.P.; and SEA VII Management, LLC — now beneficially own an aggregate 14,905,133 Class A shares, equal to 12.9 % of the outstanding Class A common stock (115,205,298 shares assumed outstanding). The bulk of the holding (14,865,346 shares) resides in Spectrum Equity VII, L.P., with two smaller funds owning 25,445 and 14,342 shares, respectively.
Recent transactions:
- Pro-rata distribution: On 2 July 2025, Spectrum Equity VII, L.P. distributed 3,989,323 Class A shares of GoodRx to its limited partners for no consideration (the “July 2025 Distribution”).
- Follow-on sales: After the distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers’ Fund, L.P. sold a combined 10,677 Class A shares in the open market, generating net proceeds of $50,606.46.
Control structure: SEA VII Management, LLC is the general partner of the other Spectrum vehicles and, together with eight named individuals, shares voting and dispositive power over the reported shares. Each individual disclaims beneficial ownership.
Implications for investors: The 3.99 million-share distribution lowers Spectrum Equity’s direct stake while increasing GoodRx’s public float, potentially improving liquidity but signalling a partial exit by an early sponsor. Despite the reduction, Spectrum Equity remains a >10 % beneficial owner, so it continues to be a significant shareholder with aligned interests, although further sell-downs remain possible. No other material changes, litigation matters or additional share transactions were reported in the past 60 days.
FAQ
What is the current stock price of Goodrx Holdings (GDRX)?
What is the market cap of Goodrx Holdings (GDRX)?
